Status | Study |
Not yet recruiting |
Study Name: Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Condition: Plasma Cell Leukemia in Remission Plasma Cell Myeloma Date: 2017-03-29 Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation |
Completed |
Study Name: Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 Condition: Multiple Myeloma Date: 2016-08-04 Interventions: Drug: PAD-VCD 12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) |
Recruiting |
Study Name: UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Condition: Acute Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Date: 2016-03-24 Interventions: Drug: Fludarabine Both Arms: 3 |
Recruiting |
Study Name: Allo HSCT Using RIC for Hematological Diseases Condition: Acute Myelogenous Leukemia Acute Lymphocytic Leukemia Chro Date: 2016-01-19 Interventions: Drug: Allopurinol 300 mg/day ( |
Recruiting |
Study Name: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Condition: Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia S Date: 2015-09-21 Interventions: Drug: Fludarabine Days -6 thro |
Recruiting |
Study Name: Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Condition: Plasma Cell Leukemia Plasma Cell Myeloma Date: 2015-09-10 Interventions: Drug: Dexamethasone Given PO |
Recruiting |
Study Name: Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Condition: Plasma Cell Leukemia Recurrent Plasma Cell Myeloma Date: 2015-07-20 Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation |
Recruiting |
Study Name: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Condition: Partial Response of Multiple Myeloma or Plasma Cell Leukemia Pl Date: 2015-01-06 Interventions: Biological: Incomplete Freund's Adjuvant |
Withdrawn |
Study Name: Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma Condition: Multiple Myeloma Plasma Cell Leukemia Date: 2014-12-09 Interventions: Drug: Bendamustine Given IV Other Names: |
Not yet recruiting |
Study Name: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Condition: Acute Myeloid Leukemia (AML) Acute Lymphocytic Leukemia (ALL) Date: 2013-10-10 Interventions: Drug: Fludarabine 25 mg/m^2 IV |